GlassScriptPhysician profile
Sergio J Xiques
NPI 1922096130
$23,644.48
in general payments reported to CMS, 2019-2025
73 companies · $4,206 in 2025
The $4,206 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,727 · 2020: $2,662 · 2021: $2,446 · 2022: $3,316 · 2023: $3,520 · 2024: $3,768 · 2025: $4,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $1,045 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,250.10 |
| Education | $1,044.79 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,697.30 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $2,547.24 | 2019-2025 | |
| Janssen Biotech, INC. | $2,417.32 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Celgene Corporation | $1,797.81 | 2019-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $1,587.72 | 2019-2025 | Xtandi, Xospata, Padcev |
| Abbvie INC. | $933.84 | 2019-2025 | Venclexta, Lupron Depot |
| Pfizer INC. | $860.26 | 2019-2025 | |
| Incyte Corporation | $808.41 | 2019-2025 | Jakafi |
| Tolmar Pharmaceuticals, INC. | $606.64 | 2019-2022 | |
| Lilly USA, LLC | $594.84 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $575.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $507.36 | 2019-2024 | Opdivo, Opdualag |
| Rigel Pharmaceuticals, INC. | $394.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.74 | 2022-2025 | Ninlaro, Iclusig, Alunbrig |
| Merck Sharp & Dohme LLC | $325.48 | 2019-2025 | Keytruda, Welireg |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Xiques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.